Mass Balance Study of NS-229 in Healthy Adult Males (Phase I)

Mass Balance Study of NS-229 in Healthy Adult Males (Phase I) - NS229-P1-03

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2071240076

Enrollment

Registered

2024-11-18

Start date

2024-12-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteer

Interventions

[14C]NS-229 will be orally administered in single dose.

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1) Provided written informed consent 2) Japanese male subjects 3) Body mass index (BMI) >=18.5 and <25.0 kg/m2 at the time of screening tests and hospitalization

Exclusion criteria

Exclusion criteria: 1) Subjects with active systemic infections (including tuberculosis, pneumonia, pneumocystis pneumonia, sepsis, opportunistic infections) 2) Medically problematic values of activated partial thromboplastin time (APTT) or prothrombin timeinternational normalized ratio (PT-INR) at screening 3) Subjects with a history of blood disease

Design outcomes

Primary

Measure	Time frame
Pharmacokinetics and safety of NS-229	—

Contacts

Public ContactClinical Development Operations

Nippon Shinyaku Co., Ltd.

zz_mail_clinical-trials@po.nippon-shinyaku.co.jp+81-120-40-8930

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026